<VariationArchive VariationID="239647" VariationName="NM_004168.4(SDHA):c.1432_1432+1del" VariationType="Deletion" Accession="VCV000239647" Version="18" RecordType="classified" NumberOfSubmissions="8" NumberOfSubmitters="8" DateLastUpdated="2024-06-17" DateCreated="2018-10-10" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="239836" VariationID="239647">
      <GeneList>
        <Gene Symbol="SDHA" FullName="succinate dehydrogenase complex flavoprotein subunit A" GeneID="6389" HGNC_ID="HGNC:10680" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>5p15.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="218320" stop="268746" display_start="218320" display_stop="268746" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="218355" stop="256814" display_start="218355" display_stop="256814" Strand="+" />
          </Location>
          <OMIM>600857</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_004168.4(SDHA):c.1432_1432+1del</Name>
      <CanonicalSPDI>NC_000005.10:236598:GG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>5p15.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="236599" stop="236600" display_start="236599" display_stop="236600" variantLength="2" positionVCF="236598" referenceAlleleVCF="TGG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="236714" stop="236715" display_start="236714" display_stop="236715" variantLength="2" positionVCF="236713" referenceAlleleVCF="TGG" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.236714_236715del" Assembly="GRCh37">
            <Expression>NC_000005.9:g.236714_236715del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.10" sequenceAccession="NC_000005" sequenceVersion="10" change="g.236599_236600del" Assembly="GRCh38">
            <Expression>NC_000005.10:g.236599_236600del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012339.1" sequenceAccession="NG_012339" sequenceVersion="1" change="g.23359_23360del">
            <Expression>NG_012339.1:g.23359_23360del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004168.4" sequenceAccession="NM_004168" sequenceVersion="4" change="c.1432_1432+1del" MANESelect="true">
            <Expression>NM_004168.4:c.1432_1432+1del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330758.2" sequenceAccession="NM_001330758" sequenceVersion="2" change="c.1432_1432+1del">
            <Expression>NM_001330758.2:c.1432_1432+1del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001294332.2" sequenceAccession="NM_001294332" sequenceVersion="2" change="c.1288_1288+1del">
            <Expression>NM_001294332.2:c.1288_1288+1del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_315" sequenceAccession="LRG_315">
            <Expression>LRG_315:g.23359_23360del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_315t1" sequenceAccession="LRG_315t1">
            <Expression>LRG_315t1:c.1432_1432+1del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004168.4" sequenceAccession="NM_004168" sequenceVersion="4" change="c.1432_1432+1delGG" MANESelect="true">
            <Expression>NM_004168.4:c.1432_1432+1delGG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA10582429" DB="ClinGen" />
        <XRef Type="rs" ID="878854627" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND multiple conditions" Accession="RCV000228421" Version="10">
        <ClassifiedConditionList TraitSetID="23694">
          <ClassifiedCondition DB="MedGen" ID="C5700310">Mitochondrial complex II deficiency, nuclear type 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3279992">Paragangliomas 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND Hereditary cancer-predisposing syndrome" Accession="RCV000567345" Version="4">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND multiple conditions" Accession="RCV001253762" Version="1">
        <ClassifiedConditionList TraitSetID="35427">
          <ClassifiedCondition DB="MedGen" ID="C0030421">Paraganglioma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-07-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND multiple conditions" Accession="RCV002500781" Version="1">
        <ClassifiedConditionList TraitSetID="66146">
          <ClassifiedCondition DB="MedGen" ID="C3150898">Dilated cardiomyopathy 1GG</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C5700310">Mitochondrial complex II deficiency, nuclear type 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C5543254">Neurodegeneration with ataxia and late-onset optic atrophy</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3279992">Paragangliomas 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-01-11" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND Dilated cardiomyopathy 1GG" Accession="RCV003475069" Version="2">
        <ClassifiedConditionList TraitSetID="2408">
          <ClassifiedCondition DB="MedGen" ID="C3150898">Dilated cardiomyopathy 1GG</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND Neurodegeneration with ataxia and late-onset optic atrophy" Accession="RCV003492005" Version="1">
        <ClassifiedConditionList TraitSetID="66003">
          <ClassifiedCondition DB="MedGen" ID="C5543254">Neurodegeneration with ataxia and late-onset optic atrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND not provided" Accession="RCV002508205" Version="1">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.1432_1432+1del AND Paragangliomas 5" Accession="RCV004020811" Version="1">
        <ClassifiedConditionList TraitSetID="7580">
          <ClassifiedCondition DB="MedGen" ID="C3279992">Paragangliomas 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-08" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-08" NumberOfSubmissions="8" NumberOfSubmitters="8" DateCreated="2018-10-10" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22974104</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24781757</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26556299</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29177515</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30877234</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32782288</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34750850</ID>
        </Citation>
        <DescriptionHistory Dated="2017-12-31">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="66003" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55999" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with ataxia and late-onset optic atrophy</ElementValue>
                <XRef ID="MONDO:0031006" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NDAXOA</ElementValue>
                <XRef Type="MIM" ID="619259" DB="OMIM" />
              </Symbol>
              <XRef ID="C5543254" DB="MedGen" />
              <XRef ID="MONDO:0031006" DB="MONDO" />
              <XRef Type="MIM" ID="619259" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2408" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10476" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Dilated cardiomyopathy 1GG</ElementValue>
                <XRef ID="Cardiomyopathy%2C+dilated%2C+1gg/7893" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013339" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CMD1GG</ElementValue>
                <XRef Type="MIM" ID="613642" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15684" />
                <XRef ID="15684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="154" DB="Orphanet" />
              <XRef ID="C3150898" DB="MedGen" />
              <XRef ID="MONDO:0013339" DB="MONDO" />
              <XRef Type="MIM" ID="613642" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="66146" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55999" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with ataxia and late-onset optic atrophy</ElementValue>
                <XRef ID="MONDO:0031006" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NDAXOA</ElementValue>
                <XRef Type="MIM" ID="619259" DB="OMIM" />
              </Symbol>
              <XRef ID="C5543254" DB="MedGen" />
              <XRef ID="MONDO:0031006" DB="MONDO" />
              <XRef Type="MIM" ID="619259" DB="OMIM" />
            </Trait>
            <Trait ID="16481" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 5</ElementValue>
                <XRef ID="Paragangliomas+5/9075" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013602" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0010" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PPGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15763" />
                <XRef ID="15763" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3279992" DB="MedGen" />
              <XRef ID="MONDO:0013602" DB="MONDO" />
              <XRef Type="MIM" ID="614165" DB="OMIM" />
            </Trait>
            <Trait ID="5546" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Complex 2 mitochondrial respiratory chain deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Succinate CoQ reductase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial complex II deficiency</ElementValue>
                <XRef ID="Mitochondrial+complex+II+deficiency/4824" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mitochondrial complex II deficiency, nuclear type 1</ElementValue>
                <XRef ID="MONDO:0100294" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5053" />
                <XRef ID="5053" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="3208" DB="Orphanet" />
              <XRef ID="C5700310" DB="MedGen" />
              <XRef ID="MONDO:0100294" DB="MONDO" />
              <XRef Type="MIM" ID="252011" DB="OMIM" />
            </Trait>
            <Trait ID="10476" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Dilated cardiomyopathy 1GG</ElementValue>
                <XRef ID="Cardiomyopathy%2C+dilated%2C+1gg/7893" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013339" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CMD1GG</ElementValue>
                <XRef Type="MIM" ID="613642" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15684" />
                <XRef ID="15684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="154" DB="Orphanet" />
              <XRef ID="C3150898" DB="MedGen" />
              <XRef ID="MONDO:0013339" DB="MONDO" />
              <XRef Type="MIM" ID="613642" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="35427" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="23238" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Carotid body tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Paraganglioma</ElementValue>
                <XRef ID="HP:0002668" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0000448" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CBT</ElementValue>
              </Symbol>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="C0030421" DB="MedGen" />
              <XRef ID="MONDO:0000448" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS168000" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002668" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0002670" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003004" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="23694" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16481" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 5</ElementValue>
                <XRef ID="Paragangliomas+5/9075" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013602" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0010" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PPGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15763" />
                <XRef ID="15763" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3279992" DB="MedGen" />
              <XRef ID="MONDO:0013602" DB="MONDO" />
              <XRef Type="MIM" ID="614165" DB="OMIM" />
            </Trait>
            <Trait ID="5546" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Complex 2 mitochondrial respiratory chain deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Succinate CoQ reductase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial complex II deficiency</ElementValue>
                <XRef ID="Mitochondrial+complex+II+deficiency/4824" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mitochondrial complex II deficiency, nuclear type 1</ElementValue>
                <XRef ID="MONDO:0100294" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5053" />
                <XRef ID="5053" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="3208" DB="Orphanet" />
              <XRef ID="C5700310" DB="MedGen" />
              <XRef ID="MONDO:0100294" DB="MONDO" />
              <XRef Type="MIM" ID="252011" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7580" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16481" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 5</ElementValue>
                <XRef ID="Paragangliomas+5/9075" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013602" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0010" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PPGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15763" />
                <XRef ID="15763" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3279992" DB="MedGen" />
              <XRef ID="MONDO:0013602" DB="MONDO" />
              <XRef Type="MIM" ID="614165" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="543340" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2016-07-01">
        <ClinVarSubmissionID localKey="523041|MedGen:C3279992;C1855008" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000288110" DateUpdated="2024-02-28" DateCreated="2016-07-01" Type="SCV" Version="10" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22974104</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24781757</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29177515</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30877234</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32782288</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34750850</ID>
          </Citation>
          <Comment>This variant results in the deletion of part of exon 10 (c.1432_1432+1del) of the SDHA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This variant has been observed in individuals with breast cancer, paraganglioma-pheochromocytoma syndrome, and/or renal cancer (PMID: 29177515, 30877234, 32782288, 34750850; Invitae). ClinVar contains an entry for this variant (Variation ID: 239647). Studies have shown that this variant is associated with inconclusive levels of altered splicing (Invitae). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.9:g.236714_236715del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3279992" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855008" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1299898" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2018-01-01">
        <ClinVarSubmissionID localKey="a66406|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000664480" DateUpdated="2024-05-01" DateCreated="2018-01-01" Type="SCV" Version="5" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26556299</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29177515</ID>
          </Citation>
          <Comment>The c.1432_1432+1delGG pathogenic mutation spans the coding exon 10/intron 10 boundary of the SDHA gene and results from the deletion of 2 nucleotides at nucleotide positions c.1432 and c.1432+1. The deleted region includes the last nucleotide and canonical donor site, which is highly conserved in available vertebrate species. This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with SDHA-related disease (Ambry internal data; Bausch B et al. JAMA Oncol 2017 Sep;3(9):1204-1212; van der Tuin K et al. J Clin Endocrinol Metab 2018 02;103(2):438-445). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.2:c.1432_1432+1delGG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2820804" SubmissionDate="2020-08-10" DateLastUpdated="2020-08-16" DateCreated="2020-08-16">
        <ClinVarSubmissionID localKey="NM_004168.4:c.1432_1432+1del|Pheochromocytoma;paraganglioma" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001429631" DateUpdated="2020-08-16" DateCreated="2020-08-16" Type="SCV" Version="1" SubmitterName="Cancer Variant Interpretation Group UK, Institute of Cancer Research, London" OrgID="506655" OrganizationCategory="consortium" OrgAbbreviation="CanVIG-UK" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-07-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant has been observed in a male proband with phaeochromocytoma and lung nodule. The variant has previously been reported in the literature, including in a male with glomus jugulare tumour (PMID: 29177515); a male with retroperitoneal paraganglioma (PMID 28384794); a male with gallbladder paraganglioma, pancreatic neuroendocrine tumour and metastatic prostate cancer (PMID: 32534711); and a female with thoracic paraganglioma (PMCID: PMC7209502) (PS4_moderate). The variant is absent from population database gnomAD (PM2_supporting) and is predicted to result in loss of protein function (PVS1_very_strong). Data included in classification: Prevalence in affected versus controls GT-AG 1,2 splice site variant predicted to result in loss of protein function Data not included in classification: Functional data</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>United Kingdom</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory">UK Molecular Diagnostic Labs</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.4:c.1432_1432+1del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
            </Name>
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">paraganglioma</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7904562</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5457293" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_004168.4:c.1432_1432+1del|OMIM:252011;613642;614165;619259" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002812187" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.4:c.1432_1432+1del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="252011" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613642" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614165" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="619259" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5501922" SubmissionDate="2023-01-04" DateLastUpdated="2023-01-07" DateCreated="2023-01-07">
        <ClinVarSubmissionID localKey="GDXSV:255114" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002818021" DateUpdated="2023-01-07" DateCreated="2023-01-07" Type="SCV" Version="1" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24781757, 22974104, 31263571, 16199547, 30877234, 29177515, 26556299, 34750850, 32782288, 35053433)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="5" alternateAllele="-" referenceAllele="GG" start="236714" stop="236715" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:1513074</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_155_20230104054205</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7917728" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2024-02-04">
        <ClinVarSubmissionID localKey="NM_004168.4:c.1432_1432+1delGG|MedGen:C5543254" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004241806" DateUpdated="2024-02-04" DateCreated="2024-02-04" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">30877234</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32782288</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34750850</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29177515</ID>
          </Citation>
          <Comment>Variant summary: SDHA c.1432_1432+1delGG is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-06 in 251166 control chromosomes (gnomAD). c.1432_1432+1delGG has been reported in the literature in individuals affected with paraganglioma or cancers including renal cancer (van der Tuin_2018, Ben Aim_2019, Hartman_2020, Parisien-La Salle_2022). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 29177515, 30877234, 34750850, 32782288). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.4:c.1432_1432+1delGG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C5543254" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14175850</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9142185" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="101784903|OMIM:614165" />
        <ClinVarAccession Accession="SCV004933610" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="5" alternateAllele="T" referenceAllele="TGG" start="236713" stop="236715" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">101784903</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614165" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7853778" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_004168.4:c.1432_1432+1del|OMIM:613642" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004202368" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.4:c.1432_1432+1del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613642" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5457293" TraitType="Disease" MappingType="XRef" MappingValue="619259" MappingRef="OMIM">
        <MedGen CUI="C5543254" Name="Neurodegeneration with ataxia and late-onset optic atrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="543340" TraitType="Disease" MappingType="XRef" MappingValue="C1855008" MappingRef="MedGen">
        <MedGen CUI="C5700310" Name="Mitochondrial complex II deficiency, nuclear type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7917728" TraitType="Disease" MappingType="XRef" MappingValue="C5543254" MappingRef="MedGen">
        <MedGen CUI="C5543254" Name="Neurodegeneration with ataxia and late-onset optic atrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5501922" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457293" TraitType="Disease" MappingType="XRef" MappingValue="252011" MappingRef="OMIM">
        <MedGen CUI="C5700310" Name="Mitochondrial complex II deficiency, nuclear type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457293" TraitType="Disease" MappingType="XRef" MappingValue="613642" MappingRef="OMIM">
        <MedGen CUI="C3150898" Name="Dilated cardiomyopathy 1GG" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="543340" TraitType="Disease" MappingType="XRef" MappingValue="C3279992" MappingRef="MedGen">
        <MedGen CUI="C3279992" Name="Paragangliomas 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1299898" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2820804" TraitType="Disease" MappingType="Name" MappingValue="paraganglioma" MappingRef="Preferred">
        <MedGen CUI="C0030421" Name="Paraganglioma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9142185" TraitType="Disease" MappingType="XRef" MappingValue="614165" MappingRef="OMIM">
        <MedGen CUI="C3279992" Name="Paragangliomas 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457293" TraitType="Disease" MappingType="XRef" MappingValue="614165" MappingRef="OMIM">
        <MedGen CUI="C3279992" Name="Paragangliomas 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7853778" TraitType="Disease" MappingType="XRef" MappingValue="613642" MappingRef="OMIM">
        <MedGen CUI="C3150898" Name="Dilated cardiomyopathy 1GG" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2820804" TraitType="Disease" MappingType="Name" MappingValue="Pheochromocytoma" MappingRef="Preferred">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

